Should erlotinib be coadministered with whole-brain radiotherapy in patients with brain metastases and non-small-cell lung cancer?

Journal of Clinical Oncology

Volumn 31, Issue 25, 2013, Pages 3164-3165

  Chamberlain, Marc C ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

BRAIN METASTASIS; CANCER RADIOTHERAPY; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT RESPONSE; WHOLE BRAIN RADIOTHERAPY; ASSESSMENT OF HUMANS; BLOOD BRAIN BARRIER; DIZZINESS; FOLLOW UP; GRADED PROGNOSTIC ASSESSMENT; HEADACHE; MAINTENANCE THERAPY; NEUROTOXICITY; NON SMALL CELL LUNG CANCER; RADIATION INJURY; TREATMENT OUTCOME; BRAIN TUMOR; DRUG ANTAGONISM; FEMALE; GENETICS; LUNG TUMOR; MALE; METASTASIS; MUTATION; NOTE; PATHOLOGY; SKULL IRRADIATION;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CRANIAL IRRADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84886571517     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.0710     Document Type: Letter

References (8)

1. Welsh JW, Komaki R, Amini A, et al: Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer. J Clin Oncol 31:895-902, 2013
2. Prados MD, Chang SM, Butowski N, et al: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579-584, 2009
3. Soffietti R, Kocher M, Abacioglu UM, et al: A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J Clin Oncol 31:65-72, 2013
4. Kocher M, Soffietti R, Abacioglu U, et al: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29:134-141, 2012
5. Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10:1037-1044, 2009
6. Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425, 2012
7. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963-1972, 2009
8. Sperduto PW, Wang M, Robins HI, et al: A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Biol Phys 85:1312-1318, 2013